EXAS News

Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates

Exact Sciences shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the details.

November 5, 2024

Exact Sciences Sees FY24 Total Revenue $2.730B-$2.750B Vs $2.832B Est.

EXAS

November 5, 2024

Exact Sciences Q3 2024 GAAP EPS $(0.21) Misses $(0.20) Estimate, Sales $709.00M Miss $717.66M Estimate

EXAS

November 5, 2024

Exact Sciences Announced That A District Court Judge Denied In Part Geneoscopy's (Defendant) Motion To Dismiss A Patent Infringement Lawsuit Filed By Exact Sciences (Plaintiff) In The United States District Court For The District Of Delaware

EXAS

May 21, 2024

Exact Sciences Option Alert: May 20 $58 Calls Sweep (38) near the Ask: 285 @ $4.0 vs 0 OI; Ref=$57.77

EXAS

April 28, 2022

Exact Sciences's Return On Capital Employed Insights

EXAS

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

April 28, 2022

Exact Sciences Highlights Updated, Expanded American Society Of Clinical Oncology Guidelines That Recommend Use Of Co.'s Oncotype Breast Recurrence Score Test

EXAS

April 28, 2022